Somatostatin receptor scintigraphy in non-medullary thyroid cancer.
8 patients with papillary cancer (4 with metastases, 4 in remission), 7 follicular cancer patients (6 with metastases), 2 patients with anaplastic thyroid cancer and 4 other non-medullary thyroid cancer patients all received an intravenous bolus injection of 220 MBq [111In-DTPA-D-Phe1]octreotide. Planar anterior and posterior gamma camera images of head-neck, chest and abdomen were obtained 24 and 48 h after injection. All primary cancers showed [111In-DTPA-D-Phe1] octreotide uptake; none occurred in patients in remission. The results were compared with conventional radio-iodine scintigraphy in patients with metastasised, differentiated thyroid cancer.
Postema
P T
PT
Department of Internal Medicine III, University Hospital, Rotterdam, The Netherlands.
De Herder
W W
WW
Reubi
J C
JC
Oei
H Y
HY
Kwekkeboom
D J
DJ
Bruining
H J
HJ
Bonjer
J
J
van Toor
H
H
Hennemann
G
G
Krenning
E P
EP
D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging* / Q000378:metabolism*; D018265:Carcinoma, Papillary, Follicular / Q000000981:diagnostic imaging* / Q000378:metabolism*; D006801:Humans; D007205:Indium Radioisotopes; D009362:Neoplasm Metastasis / Q000175:diagnosis; D015282:Octreotide / Q000031:analogs & derivatives; D004369:Pentetic Acid / Q000031:analogs & derivatives; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000378:metabolism*; D013725:Terbium; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*
D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D013725:Terbium; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide